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Spinal Muscular Atrophy is due to the loss of SMN1 gene 
function. The duplicate gene SMN2 produces some, but 
not enough, SMN protein because most transcripts lack 
exon 7. Thus, promoting the inclusion of this exon is a 
therapeutic option. We show that a somatic gene therapy 
using the gene for a modified U7 RNA which stimulates 
this splicing has a profound and persistent therapeutic 
effect on the phenotype of a severe Spinal Muscular Atro-
phy mouse model. To this end, the U7 gene and vector 
and the production of pure, highly concentrated self-
complementary (sc) adenovirus-associated virus 9 vector 
particles were optimized. Introduction of the functional 
vector into motoneurons of newborn Spinal Muscular 
Atrophy mice by intracerebroventricular injection led 
to a highly significant, dose-dependent increase in life 
span and improvement of muscle functions. Besides the 
central nervous system, the therapeutic U7 RNA was 
expressed in the heart and liver which may additionally 
have contributed to the observed therapeutic efficacy. 
This approach provides an additional therapeutic option 
for Spinal Muscular Atrophy and could also be adapted 
to treat other diseases of the central nervous system with 
regulatory small RNA genes.
Received 4 May 2016; accepted 18 July 2016; advance online  
publication 30 August 2016. doi:10.1038/mt.2016.152
INTRODUCTION
The severe, hereditary, neuromuscular disorder Spinal Muscular 
Atrophy (SMA)1 is due to deletions or mutations of both alleles 
of the essential survival motor neuron 1 (SMN1) gene.2 A second 
gene copy located in the same 5q13 region of the human genome 
(SMN2)3 allows patients to survive embryonic and fetal develop-
ment, but only partly compensates for the loss of SMN1 in postna-
tal life. The reason for this reduced functionality is that, in contrast 
to SMN1, the exon 7 of SMN2 is preferentially skipped, leading to 
the synthesis of a shortened and unstable protein.4 This increased 
skipping is due to a C to T transition at position 6 of exon 7 which 
transforms an exonic splicing enhancer interacting with the splic-
ing factor SRSF1 into an hnRNP A1/A2B1-dependent exonic 
splicing silencer.5–8
Because all SMA patients contain at least one SMN2 copy, the 
splicing of this gene is an attractive therapeutic target. Previous 
work from our laboratory provided the first proof of principle 
that a correction of SMN2 splicing can improve the condition of a 
mouse SMA model. We had developed a modified U7 snRNA gene 
carrying an antisense sequence complementary to SMN exon 7 
and an additional sequence able to bind the positive splicing fac-
tor SRSF1 (U7-ESE-B) and had shown that this construct stimu-
lates exon 7 inclusion and SMN protein synthesis in cell culture 
models, including patient cells.9 We then generated transgenic 
mice containing the U7-ESE-B transgene and crossed it into the 
background of severe SMA mice (Smn1−/−, SMN2+/+) that nor-
mally survive only for 5–7 days.10 With the additional U7-ESE-B 
transgene, the mice survived for a median of 150 days, and both 
the survival and the extent of phenotypic rescue were dependent 
on the copy number of the transgene.11
Since then, similar results have been obtained with anti-
sense oligonucleotides that bind to various parts of the SMN2 
pre-mRNA.12,13 In particular, a phosphorodiamidate morpholino 
oligonucleotide targeting a splicing silencer in intron 7 (ISS-N1) 
showed a high efficiency in vitro and significantly prolonged the 
survival of SMN∆7 mice (Smn1−/−, SMN2+/+, SMN∆7 +/+; 
normally surviving for ~12 days14).15,16 Additionally, several 
groups have shown that SMN1 cDNA expression cassettes in self- 
complementary (sc) adenovirus-associated virus (AAV) vectors 
can increase survival and lead to a virtually complete rescue in 
the SMN∆7 mouse SMA model17–21 and in an experimental pig 
model for SMA.22
Despite these very promising advances, some of which are 
already being tested in clinical trials,23 the development of other 
therapeutic approaches for SMA, including our U7 snRNA strat-
egy, should continue. It is still important to explore additional 
options for treating SMA patients, as it is not yet clear how effi-
cient and safe the currently available options will be in a clinical 
setting.
Concerning the U7-mediated correction of SMN2 splicing, 
the major open question has been whether it can be effective 
in a somatic gene therapy context, as opposed to the previous 
transgenic approach where SMN2 splicing is corrected from the 
moment of conception. Here, we demonstrate that this is indeed 
the case. We have constructed scAAV vectors which contain vari-
able numbers of U7-ESE-B expression cassettes. When scAAV9 
vector particles containing four tandem copies of the U7-ESE-B 
gene are injected into the cerebral ventricle of newborn SMN∆7 
mice, this results in a dose-dependent increase in life span 
and improvement of muscle functions. We also show that the 
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therapeutic U7 RNA is expressed in the heart and liver which may 
contribute to its therapeutic effect.
RESULTS
Improved efficiency of scAAV compared with ssAAV 
vectors
The U7 snRNA derivative U7-ESE-B used to correct SMN2 exon 
7 splicing contains, from 5′ to 3′ (Figure 1): a repeat of three tar-
get sequences for the splicing factor SRSF1, an antisense sequence 
complementary to nucleotides 31–48 of SMN2 exon 7, an opti-
mized Sm binding site that interacts with the seven Sm proteins 
and ensures nuclear localization, and a 3′ hairpin that stabilizes 
the RNA.9,11 To accommodate multiple copies of U7-ESE-B into 
AAV vectors, we shortened the original gene while retaining all 
necessary promoter and 3′ elements, i.e., the distal sequence ele-
ment or octamer sequence, the proximal sequence element, and 
the 3′ box.24
We initially cloned a single copy of this shortened U7-ESE-B 
gene (1xsU7) into separate vectors allowing the production of 
either single-stranded (ss) or scAAV particles (see Supplementary 
Figure S1). Because of an additional enhanced green fluorescence 
protein (EGFP) cassette present in the ssAAV, the two vectors 
are of similar size with regard to both the plasmid and the DNA 
packed into virions. HeLa S2 cells containing a SMN2 minigene 
reporter9,25 were then transduced with AAV serotype 6 particles. 
With both ss and scAAV particles, an increase in SMN2 exon 7 
inclusion was detectable after 9 hours post-transduction (Figure 
2a). However, in the scAAV 1xsU7-transduced cells, the exon 
7-containing transcripts prevailed between 12–24 hours post-
transduction whereas the cells transduced with AAV-EGFP 1xsU7 
(ss) kept considerable levels of RNA lacking exon 7 throughout 
the experiment. These differences between the two vectors cor-
related with the measurements of U7-ESE-B RNA by reverse 
transcriptase-quantitative polymerase chain reaction  (RT-qPCR) 
(Figure 2b). The ratio of splicing products returned to the uncor-
rected level after 48 hours, presumably because the AAV genomes 
were diluted out in these dividing cells (data not shown).
Multiple copies of the U7-ESE-B gene result in more 
efficient splicing correction
We then tried to improve our scAAV vector by inserting four and 
five copies of the sU7 cassette (see Supplementary Figure S1). 
In direct comparison, ~10 times more scAAV 1xsU7 than scAAV 
5xsU7 were required to obtain a comparable level of splicing cor-
rection in HeLa S2 cells (Figure 3a). Accordingly, scAAV 1xsU7 
Figure 1  Schematic representation of U7-ESE-B snRNA used to 
improve SMN2 exon 7 splicing. (a) The U7-ESE-B splicing correction 
cassette9,11 contains an antisense sequence directed to the 3′ part of 
exon 7 of the human SMN2 gene (orange) and an additional splicing 
enhancer sequence consisting of repeated binding motifs for splicing 
factor SRSF1 (yellow). The modified U7 moiety is represented by its 
3′-terminal hairpin and its Sm protein core (pictured as a blue ring). 
Within exon 7, the C–U transition that distinguishes SMN1 and SMN2, 
the central ESE (SE2) and the UAA stop codon are indicated with pink 
letters. (b) Structure of the shortened U7-ESE-B cassette (sU7). The distal 
sequence element or octamer motif (DSE) and the proximal sequence 
element (PSE) of the U7 promoter as well as the 3′ box determining 
proper 3′ end formation are indicated by orange boxes. The splicing 
enhancer sequence (ESE), the antisense sequence and the modified Sm 
binding site recognizing the seven canonical Sm proteins present in spli-
ceosomal snRNPs (Sm OPT) are shown in similar colors as in a.
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Figure 2 Comparison of single-stranded (ss) and self-complemen-
tary (sc) adenovirus-associated virus (AAV) vectors in cell culture. 
HeLa S2 cells were transduced with AAV serotype 6 particles of the vec-
tors AAV-EGFP 1xsU7 ss and scAAV 1xsU7 at a concentration of 500 vg/
cell and analyzed for the splicing of the SMN2 minigene present in these 
cells by reverse transcriptase-polymerase chain reaction (RT-PCR) and 
agarose gel electrophoresis (a) and for the concentration of U7-ESE-B 
RNA by RT-quantitative PCR (RT-qPCR) (b). The RT-PCR for SMN2 splic-
ing produces amplicons containing and lacking exon 7 as well as a more 
slowly migrating band corresponding to heterodimers (hd). All samples 
shown are from a single experiment with duplicate assays for each vari-
able. The samples were processed together but analyzed on four dif-
ferent agarose gels. The RT-qPCR data have been compiled from three 
biological replicates analyzed with duplicate measurements. The curves 
were fitted with a third order polynomial function contained in the Excel 
program. The levels of 7SK snRNA were used for normalization.
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produced only 20–45% of the U7-ESE-B RNA amount generated 
by scAAV 5xsU7 of identical titer (Figure 3b). In contrast, scAAV 
5xsU7 and scAAV 4xsU7 showed very similar efficiencies of exon 
7 splicing correction (Figure 3c). A likely reason for this is that 
the size of scAAV 5xsU7 exceeds the known packaging capacity 
of AAV virions.26 Thus, scAAV 5xsU7 genomes may get packaged 
less efficiently or partly truncated during packaging. This inter-
pretation is supported by the fact that scAAV 4xsU7 generally 
yielded more viral particles than scAAV 5xsU7 (not shown).
Dose-dependent improvement of SMA condition in 
the SMNΔ7 mouse model
Based on these results, we decided to test scAAV 4xsU7 in somatic 
gene therapy experiments in the SMNΔ7 mouse model (Smn1 −/−, 
SMN2 +/+, and SMN∆7 +/+) for a severe form of SMA. Thus, we 
generated scAAV particles of serotype 9 which had been shown 
to transduce motoneurons efficiently after intravenous (i.v.) or 
intracerebroventricular (icv) injection of newborn mice.27,28 We 
injected 5 µl of purified particles of different concentrations into 
the cerebral ventricle of mice on the day of birth (P0). For all 
preparations, except for the least concentrated one, we performed 
a second injection on the next day (P1). As can be seen from the 
survival (Figure 4a) and weight development curves (Figure 4b), 
all these injections significantly increased the survival and growth 
of the animals, albeit to a different extent, depending on the vector 
dose injected. With the lowest dose of 4.07 × 1012 vector genomes 
(vg) per kg body weight, the mice reached a maximum weight of 
6.5 g and survived for 22 days, compared with 4.3 g and 12 days, 
respectively, for the phosphate-buffered saline (PBS)-injected 
controls (all median values). Two mice treated with the two high-
est vector doses of 2.27 × 1014 vg/kg and 4.34 × 1013 vg/kg are still 
alive on days 215 and 182, respectively (at the time of resubmis-
sion of this manuscript), and have reached body weights of ~21 g. 
In comparison, one of four mice treated with 3.23 × 1013 vg/kg 
body weight of the cDNA vector survived beyond day 200 and 
progressed to a body weight of 32 g. Thus, a similar therapeutic 
effect can be reached by the somatic application of the short-
ened U7-ESE-B cassette as with SMN cDNA, but a higher vector 
dose is required (see summary in Table 1). Note that we could 
not observe any effect on growth or survival when wild-type or 
SMA carrier mice were injected with scAAV9 4xsU7 (data not 
shown). A plot of the effectively injected doses against the maxi-
mal survival of the mice shows that the therapeutic effect is dose-
dependent (Figure 4c) and that there seems to be a threshold for 
prolonged survival of ~4 × 1013 vg/kg.
We evaluated the muscle performance of injected mice while 
they could still be compared with PBS-injected controls, i.e., 
between days P1–P15. In the tube hanging test, mice injected with 
≥5 × 109 vg/kg of scAAV9 4xsU7 surpassed the uninjected or PBS-
injected control mice (see Supplementary Figure S2a). This differ-
ence was statistically significant from P3–P10 (P = 0.0075, two-sided 
T-test). For the hindlimb splay test, the difference between the two 
groups was significant for measurements between P8–P10 (P = 
0.028) (see Supplementary Figure S2b). In the righting test, the 
differences for individual days were only significant on the days 
P9 and P10 (P < 0.05) (see Supplementary Figure S2c). However, 
combining all values measured from P1–P15, the mean time to 
right in mice injected with ≥5 × 109 vg/kg was 30 seconds com-
pared with 43 seconds for the SMA controls (P = 4.3 × 10−5). That 
this test has a relatively high variability was found in a previously 
published power analysis.29
Most importantly, the mice treated with the higher doses of 
scAAV9 4xsU7 survived much longer than control SMNΔ7 mice. 
They grew to a smaller size compared with wild-type or SMA car-
rier littermates and often displayed signs of milder SMA models 
such as partial necrosis of the tail and ear pinnae. Despite these 
symptoms, they were active and able to feed and drink without 
assistance. Supplementary Figure S3 shows selected photographs 
of such mice, and video sequences are available as Supplementary 
Files S2–S4.
We further measured U7-ESE-B RNA levels by RT-qPCR at 
P10 in mice injected with 8 × 1013 vg/kg. The therapeutic RNA 
Figure 3 Comparison of splicing correction by self-complementary adenovirus-associated virus (scAAV) vectors with different numbers 
of U7-ESE-B cassettes. HeLa S2 cells were transduced with AAV serotype 6 particles of scAAV 5xsU7 and scAAV 1xsU7 (a,b) or scAAV 5xsU7 and 
scAAV 4xsU7 (c). SMN2 minigene splicing assays a,c and measurements of U7-ESE-B RNA b were performed as in Figure 2. All samples were 
collected 24 hours post-transduction. The vector concentrations are indicated as vector genome excess over cells. For example, 5× indicates a 
concentration of 5 vg/cell. Error bars indicate standard deviations from two biological replicates carried out in duplicate.
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was expressed in the brain, spinal cord, and liver at a similar level 
as endogenous U6 snRNA (Figure 5a). Surprisingly, the heart 
showed the highest expression. In contrast, U7-ESE-B RNA lev-
els were low in the lung and not reproducibly detectable in the 
diaphragm and kidney. As expected, no tissues from SMA or car-
rier mice injected with PBS produced positive RT-qPCR signals 
for U7-ESE-B RNA.
Additionally, we analyzed whether SMN2 splicing gets cor-
rected at P10 in these mice. A statistically significant increase in 
the amount of exon 7-containing SMN2 mRNA could be detected 
in the liver (Figure 5b). For the brain, spinal cord, and heart, there 
was also a tendency toward higher exon 7 inclusion which was, 
however, not significant for the limited number of samples ana-
lyzed. In contrast, the lung, kidney, and diaphragm that contained 
very little or no U7-ESE-B RNA also did not show elevated levels 
of exon 7-containing SMN2 mRNA.
To test whether the U7-ESE-B RNA expression can also reverse 
molecular events caused by low SMN levels, we analyzed the splic-
ing of ubiquitin specific peptidase like 1 (Uspl1). Transcripts of this 
gene are alternatively spliced in total brain or spinal cord samples 
of various SMA models.30–33 We indeed detected the alternative 
product in brain and spinal cord samples from 10 day old SMNΔ7 
mice, and its relative proportion was reduced in mice which had 
been treated with scAAV9 4xsU7 (Figure 5c).
We further tested whether SMN protein is expressed in moto-
neurons by subjecting spinal cord sections of 10 day old mice to 
immunohistochemistry. Motoneurons were identified based on 
their location in the ventral horn, their morphology and their 
staining with anti-choline acetyl transferase (ChAT) antibody 
(Figure 6). The staining of motoneurons with anti-SMN antibody 
was strongly reduced in SMA disease (Figure 6b) compared with 
carrier mice (Figure 6a). Most importantly, however, in SMA 
mice injected with scAAV9 4xsU7, most motoneurons showed 
SMN staining. The intensity, and presumably the transduction by 
scAAV9 4xsU7, appeared to be variable from cell to cell. While 
some motoneurons showed only a faint green staining, others had 
green and red staining of similar intensity, resulting in a yellow 
overlay (Figure 6, c1). In yet other motoneurons, the staining of 
SMN even prevailed, reflected by a green appearance of the over-
lay (Figure 6, c2).
To assess the functional morphology of neuromuscular junc-
tions (NMJs), we stained whole mount diaphragms from 10 day 
old mice with an antibody against the active zone component bas-
soon. Similar to the situation in 3 day old mice of the severe SMA 
model,34 the spots of bassoon staining were fewer and covered a 
smaller fraction of the NMJ area also in these 10 day old mice of the 
SMNΔ7 model (see Supplementary Figure S4a,b). Importantly, 
injection of 8 × 1013 vg/kg of scAAV9 4xsU7  conserved these spots 
to a level that was not significantly different from that of carrier 
mice (see Supplementary Figure S4c,d). These preliminary find-
ings will have to be corroborated with additional assessments of 
motor unit functionality, but they nevertheless suggest that the 
NMJs are much less affected in the animals treated with scAAV9 
4xsU7.
DISCUSSION
This study demonstrates that the phenotype of the SMNΔ7 mouse 
model (Smn1 −/−; SMN2 +/+; and SMNΔ7 +/+) can be consid-
erably alleviated by the postnatal administration of a modified 
U7 snRNA gene capable of correcting the splicing of the human 
SMN2 gene. The life span, growth, and muscular functions of 
Figure 4 Extended survival of SMA Δ7 mice injected with self-comple-
mentary adenovirus-associated virus 9 (scAAV9) 4xsU7. (a) Survival 
curves and (b) weight development. The mice receiving similar amounts 
of virus (vector genomes per kg body weight) have been grouped and 
are identically color-coded in a and b. In the groups which received the 
highest concentrations of scAAV9 4xsU7, mice are still surviving (one of 
five for 4.34 × 1013 and one of three for 2.27 × 1014; marked by asterisks in 
a. Deeper dents in the weight curves in b usually indicate when a mouse 
from the group became severely ill and had to be killed. Error bars in b 
indicate standard deviations. (c) Dose response curve. The actual virus 
amount received by each mouse is plotted against the time when it died 
or had to be killed. Orange points mark mice that are still alive. The 
red dotted line indicates the median survival of spinal muscular atrophy 
(SMA) Δ7 mice which either received no injection or were injected with 
phosphate-buffered saline (PBS) (12 days). The trendline was fitted with 
a second order polynomial function.
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the treated mice have all been improved significantly (Figure 4, 
Supplementary Figure S2, and Table 1). This improvement also 
extends to the splicing of the SMN2 and Uspl1 mRNAs (Figure 5). 
Moreover, the immunohistochemical detection of SMN protein 
indicates that a large proportion of motoneurons have been trans-
duced by the virus (Figure 6) and NMJs of the diaphragm show 
a near normal staining for the active zone component bassoon 
whereas this staining is significantly reduced in PBS-injected 
SMA mice (see Supplementary Figure S4). All this proves that 
the correction of SMN2 mRNA splicing by the U7-ESE-B gene 
not only works in a transgenic approach11 but also in a somatic 
gene therapy setting. Most likely, the remaining symptoms such 
as the reduced adult body weight and partial necroses could be 
overcome with yet higher vector doses, as one of the mice treated 
with the highest titer still does not show any ear or tail necrosis 
after 215 days. In any case, it is debatable whether these symptoms 
(which are also observed in milder mouse SMA models) are rel-
evant for human SMA or whether they represent a mouse-specific 
response to reduced SMN levels.
The success of our approach is largely due to the choice and 
optimization of the vector. We opted for vectors of the AAV sero-
type 9 which had been shown to cross the blood-brain barrier 
and to transduce motoneurons efficiently in newborn mice,22,28 
macaques,35 cats,22 and swine.36 Our initial cell culture experi-
ments then indicated that the accumulation of U7-ESE-B snRNA 
is more rapid and the correction of SMN2 splicing is more efficient 
with a scAAV vector compared to a ssAAV vector of comparable 
insert size (Figure 2), in agreement with published information.37 
Moreover, the shortening of the U7-ESE-B cassette allowed us 
to include four tandem copies in a scAAV vector, which further 
improved the U7-ESE-B snRNA expression and correction of 
SMN2 exon 7 splicing (Figure 3). Because a construct with five sU7 
inserts, i.e., containing more DNA than the theoretical packaging 
size of scAAV, did not further improve the results and also seemed 
to yield lower viral titers, we chose the scAAV 4xsU7 construct for 
in vivo experiments. Additionally, the optimization of viral pro-
duction and purification greatly contributed to the success of our 
project. The combination of iodixanol gradient centrifugation, 
dialysis, and primary concentration on Amicon filters with a final 
concentration by ultracentrifugation yielded very pure particles of 
sufficiently high titers to elicit a prolonged therapeutic benefit.
The therapeutic effects obtained in SMNΔ7 mice with the high-
est vector doses are similar to those reported by others for scAAV9 
and scAAV8 vectors containing a SMN1 cDNA expression cas-
sette17–21 or with antisense oligonucleotides correcting SMN2 
splicing.13,15,16,38 Concerning the dose of virus necessary to obtain 
a prolonged survival, our data can best be compared with those 
of Meyer et al.,27 as both studies used similar vectors as well as the 
same mouse model and injection technique. For the SMN cDNA 
vector, Meyer et al. had to inject ~2 × 1013 vg/kg to ensure >50% 
survival of the mice beyond 100 days.27 This is in line with the 
reports of other groups who injected scAAV921 or scAAV817 by the 
icv route. In two direct comparisons, icv injections were shown to 
be more efficient than i.v. injections.21,27 In our hands, icv  injection 
of ~3 × 1013 vg/kg of the same cDNA vector used by Meyer et al.27 
produced a comparable result to their study with almost perfectly 
superimposable weight gain curves. In contrast, the threshold 
for survival beyond 100 days with scAAV9 4xsU7 seems to lie at 
~4 × 1013 vg/kg (Figure 4c). Thus, a similar therapeutic effect can 
be achieved, but the U7 approach appears to require a somewhat 
higher vector dose than the cDNA complementation. It would be 
interesting to know whether this difference in efficiency is the same 
in other species and particularly in humans, or if the U7-ESE-B 
RNA and/or the SMN cDNA are expressed with a different effi-
ciency in other species. In pigs, 1 × 1013 vg/kg to 4 × 1013 vg/kg of 
an scAAV9 vector carrying human SMN cDNA improved an SMA 
phenotype provoked by SMN RNA interference.36
The higher vector dose required to obtain a therapeutic benefit 
with scAAV9 4xsU7 may raise some concern, as it may be asso-
ciated with a higher rate of genome insertions. Although AAV 
vectors are considered to remain episomal, integration into the 
genome has been reported to occur at a frequency of 10–4–10–5 
and to be random but without activating nearby genes.39–41 To 
date, one study has described the development of hepatocellular 
carcinoma about 1 year after i.v. injection of ~7 × 1013 AAV vg/kg 
into newborn mice.42 However, the risk of AAV vector-mediated 
insertional mutagenesis remains controversial, as other authors 
could not induce liver cancer in adult mice after injection of AAV 
viral vectors at doses up to 1014 vg/kg via the portal vein and 18 
months follow-up.43,44 Moreover, AAV vector-mediated cancer 
development has not been observed so far in nonhuman primates 
or in human clinical trials.40,41,45 In our case, an additional fac-
tor that likely reduces the risk of insertional mutagenesis is the 
fact that we are using a U snRNA transgene. In contrast to cDNA 
expression vectors that require a strong promoter/enhancer to 
drive expression of the transgene, the U7 gene is unlikely to cause 
Table 1 Overview of viral injection experiments.
Virus type
Median  
dose (vg/kg)
Max weight Median 
Survival (day)
P-valuesb N
Age (day)a Percentb LMCc dGBWd
Untreated 0 9 61 12 12
cDNA 3.23E+13 98 90 122 0.0019 0.0090 4
4xsU7 4.07E+12 11 88 22 0.0058 0.0227 3
4xsU7 1.75E+13 13 61 25.5 0.0001 0.0010 7
4xsU7 3.21E+13 20 58 33 0.0058 0.0227 3
4xsU7e 4.34E+13 24 70 34 0.0007 0.0037 5
4xsU7e 2.27E+14 180 64 195 0.0058 0.0227 3
aMedian age when maximal weight was reached. b% of normal weight of wt/carriers at same age. cComparison of survival to untreated mice by log-rank Mantel 
Cox test. dComparison of survival by Gehan-Breslow-Wilcoxon Test. eAnimals still alive, observation ongoing.
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enhancer-mediated activation of nearby genes, as U snRNA pro-
moters and transcription complexes are distinct from those of 
protein-coding genes.46
In any case, neither the scAAV nor the therapeutic U7-ESE-B 
RNA appears to exert any unwanted side effects. First, control 
animals injected with the vector did not show any disease symp-
toms and developed normally. Most importantly, however, we 
have bred Smn1 +/− carriers of the transgenic SMA/U7 mouse 
line carrying 5–8 copies of the U7-ESE-B transgene embedded in a 
lentiviral vector backbone for 17 generations (SMA/U7 mice (For 
corrected nomenclature, see https://www.jax.org/strain/025102) 
can be obtained from Jackson Laboratories (Stock# 25102)). These 
mice never showed any unwanted side effects, had a completely 
normal behavior, activity and appearance as well as a normal 
fertility. Moreover, the Smn1 −/− animals of this line showed an 
improvement and partial reversal of most SMA symptoms (mus-
cle activity, growth and life span, histological and immunohis-
tological features of spinal cord and NMJs, and gene expression 
profiles).11,30,34,47,48
The question whether SMN expression needs to be restored 
only in motoneurons, in cells of peripheral organs, or both, has 
received increased attention following the recent observation of 
Krainer and coworkers who found that an antisense oligonucle-
otide correcting SMN2 splicing worked as well when injected 
subcutaneously, as when the icv route was used.38 Moreover, the 
beneficial effect of the peripheral application was not abolished 
by the icv injection of sense oligonucleotides which should have 
neutralized the antisense oligos in the central nervous system.16 
These findings contrast with the observations of various groups 
that icv injection of scAAV vectors expressing SMN cDNA 
are more effective than i.v.21,27 or intramuscular49 injections. 
Moreover, a study using germ-line transgenesis of the severe 
SMA model with SMN cDNA under the control of different cell 
type-specific promoters showed that a neuron-specific expres-
sion rescued the mice from SMA whereas an expression under 
a muscle-specific promoter failed to do so, except when it also 
induced a low level of SMN expression in the central nervous sys-
tem.50 More recent experiments using cre recombination induced 
by the ChAT and Nestin promoters indicated that ChAT-cre 
mediated SMN gene repair (i.e., restricted to cholinergic neu-
rons) is sufficient to restore motor unit function and, in combi-
nation with Nestin-cre, which additionally allows the production 
of functional SMN in glial cells, can extend survival and induce 
an almost complete phenotypic rescue.51 Even though our data 
do not directly address the question of peripheral requirements 
for high SMN levels, it is interesting to note that we detected 
expression of U7-ESE-B RNA and SMN2 splicing correction in 
the liver and heart (Figure 5b). High transduction of the liver 
after icv injection of AAV9 encoding sulfamidase into 2 month 
old mice has been observed in a study on mucopolysaccharidosis 
IIIA, but the heart was not transduced with this vector system.52 
In contrast, both liver and heart are efficiently transduced after 
iv injections of AAV9 in mice.53 Our results suggest that scAAV9 
injected icv in newborn mice can pass the blood brain barrier 
and reach peripheral organs that are susceptible to infection by 
this serotype. This additional expression of U7-ESE-B RNA in the 
heart and liver may contribute to its therapeutic effect, because 
cardiac defects have been observed in SMA patients54 and mouse 
models55–57 and a liver dysfunction may play a role, at least in the 
Taiwanese SMA mouse model.38
In conclusion, our study proves that it is feasible to promote the 
inclusion of a skipped exon and to obtain a pronounced improve-
ment of a severe SMA phenotype by a somatic gene therapy approach 
Figure 5 Functional characterization of Spinal Muscular Atrophy 
(SMA) Δ7 mice injected with self-complementary adenovirus-associ-
ated virus 9 (scAAV9) -4xsU7. (a) U7-ESE-B RNA expression measured by 
reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). 
In two separate injection experiments, mice were injected with 8 × 1013 
vg/kg of the same preparation of scAAV9 4xsU7 (AAV1 and AAV2) or with 
phosphate-buffered saline (PBS) as control (PBS1 and PBS2). For each 
experiment, the data of AAV-injected SMA animals and PBS-injected carri-
ers have been averaged. Numbers in parentheses indicate the numbers of 
animals. The values of all PBS-injected animals were below the 1% thresh-
old limit of the graph. (b) Expression of exon 7-containing SMN2 mRNA. 
a.u., arbitrary units, expression levels were normalized with respect to 
actin mRNA and the numbers multiplied by 1,000. Numbers of AAV-
injected (Smn1−/−) animals: two for lung, kidney, diaphragm; four for 
other tissues. PBS injected controls (Smn1 −/− and +/−): four and seven, 
respectively. Asterisk: statistical relevance (P = 0.0107, two-sided T-test). 
Error bars indicate standard deviations. (c) Detection of alternatively 
spliced Ubiquitin Specific Peptidase Like 1 (Uspl1) transcripts by reverse 
transcriptase-polymerase chain reaction (RT-PCR). All RNA samples used 
in this figure were isolated from 10 day old mice.
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with a modified U7 snRNA derivative. A possible application of this 
method to human SMA therapy will depend, among other things, 
on the advance of other therapeutic approaches. Clinical trials are 
ongonig for AAV-based SMN cDNA vectors and antisense oligo-
nucleotides.23 Additionally, a small molecule drug which corrects 
SMN2 splicing has shown very promising results in preclinical stud-
ies.58,59 However, it is not yet clear which treatment option will be 
most efficient and have the least side-effects in human SMA patients. 
A possible argument for gene therapies is that a single treatment can 
in principle lead to a life-long cure of SMA, whereas an oligonucle-
otide or small molecule drug will require repeated interventions, 
even if the compounds are very stable as is the case for some oli-
gonucleotides. On the other hand, a gene therapy is more difficult 
to apply and may represent an additional burden for the patients, 
especially if children are treated at a very young age. In any case, 
there is room for exploring additional treatment options such as our 
U7-based approach or the recently described method using exon-
specific U1 snRNAs which has been demonstrated to alleviate SMA 
symptoms in a mouse transgenic approach60 but has not yet been 
tested in a somatic gene therapy setting.
Apart from the relevance of the present findings for SMA, it is 
conceivable to use an approach similar to ours to introduce other 
noncoding regulatory RNAs into the central nervous system. This 
could be used either to modulate specific phenotypes in experi-
mental animals or to improve other kinds of neurological or neu-
romuscular disorders.
MATERIALS AND METHODS
Cell lines. HeLa S2 are HeLa cells that have been stably transformed with a 
human SMN2 minigene25 as described.9 AAV-293 cells containing adeno-
virus type 5 DNA and expressing the adenovirus E1 gene were obtained 
from Agilent. All cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum (BioConcept), 100 U/ml peni-
cillin and 100 U/ml streptomycin (both Lubio Science). This medium is 
called DMEM+/+; medium without fetal calf serum and antibiotics will 
be referred to as DMEM−/−. The cells were kept at 37°C in a humid atmo-
sphere with 5% CO2.
AAV production and purification
Expression plasmids. To accommodate multiple copies of the U7-ESE-B 
cassette in AAV vectors, we shortened the original cassette at the 5′ and 3′ 
ends while retaining all necessary promoter and 3′ elements. The resulting 
short U7-ESE-B cassettes (sU7) contain 253 and 104 bp of 5′ and 3′ flanking 
sequences, respectively. As recipient plasmids to generate ss and scAAV, we 
used pAAV-CMV-eGFP61 and pAAVsc_U7Dtex23,62 respectively. We gen-
erated constructs containing one to five copies of sU7. In some vectors, we 
inserted an EGFP expression cassette in the plasmid backbone to be able 
to monitor the transfection efficiency during virus production. Maps are 
shown in Supplementary Figure S1. Sequence files and further informa-
tion on the cloning are available upon request.
Helper plasmids. For AAV6 production, we used the helper plasmid 
pDF6.63 For AAV9, the separate helper plasmids Rep2-Cap9 and pHelper 
were used.28
Detailed procedures for the production and purification of AAV 
vectors are described in the Supplementary Materials and Methods and 
Supplementary Table S1. An overview of the method is presented in 
Supplementary Figure S5.
qPCR based virus titration. Virus suspensions were treated with DNase 
(10 U DNase I, Roche Diagnostics, Rotkreuz, Switzerland) for 20 minutes at 
37°C. Then, the viral capsids were destroyed by an incubation for 20 min-
utes at 95°C that simultaneously inactivated the DNase. Serial dilutions of 
the lysed virus preparation and of a reference plasmid were compared by 
qPCR. Reactions consisted of 10 µl MesaGreen qPCR Mastermix Plus for 
SYBR Assay (Eurogentec, Liège, Belgium), 0.2 µl of each primer (12 µmol/l; 
Microsynth AG, Switzerland), 5.6 µl H2O and 4 µl of sample. The qPCR was 
performed in a Rotor-Gene Q (Qiagen AG, Hombrechtikon, Switzerland) 
with initial denaturation for 10 minutes at 95°C, followed by 40 cycles of 
95°C for 15 seconds, 56–60°C (according to the primers used) for 15 sec-
onds, and 10 seconds at 70°C. A melting curve from 65–95°C was then used 
to assess the purity of the amplicon. The run was evaluated with Rotor Gene 
Q Series Software (Version 2.2.3, Build 11), Qiagen AG, Hombrechtikon, 
Switzerland. Primers are listed in Supplementary Table S2.
Plasmid transfections and viral transduction of cells. HeLa S2 cells were 
seeded at a density of 105 cells per well of a six-well plate. On the next day, 
the medium was replaced by DMEM −/−. For each well, 1.5 µg of plasmid 
and 4 µl Fugene HD (Roche) were mixed in 100 µl DMEM -/- and allowed 
to form complexes at room temperature for 15 minutes. The mixture was 
then distributed dropwise over the cells. After incubation for 4 hours at 
37°C, the medium was replaced by DMEM +/+.
Viral transductions were performed in the mnimal sufficient volume 
of medium to completely cover the cells. After 6 hours at 37°C, the 
medium was completed to the standard volume for the corresponding 
culture flask.
Mouse -breeding and genotyping. SMNΔ7 mice14 were purchased from 
Jackson Laboratories (FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1MsdTg(SMN
2*delta7) 4299AhmB/J; stock number: 005025; Bar Harbor, ME, USA) 
and kept at the central animal facility, Inselspital Bern under standard 
IVC conditions according to legal requirements (Swiss federal permit 
BE14/13). For genotyping, DNA from tail biopsies taken on the day of 
birth was extracted and analyzed with KAPA Mouse Genotyping Kits 
(Axonlab, Baden Switzerland) according to the manufacturers’ instruc-
tions. The primers used (see Supplementary Table S2) allowed us to 
determine the Smn1 genotype and sex of the animals.
Injections for somatic gene therapy in mice. AAV preparations or PBS (for 
controls) were injected into the left cerebral ventricle of newborn mice. Prior 
to injection, the virus was mixed with 0.025% Fast Green (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland) to be able to evaluate the success of the 
injection. For better visibility, the head of the mouse was held onto a small 
Figure 6 Detection of SMN protein in spinal cord motoneurons of 
Spinal Muscular Atrophy (SMA) mice. Spinal cord sections from 10 
day old mice were immunolabelled with anti-choline acetyl transferase 
(ChAT) to identify cholinergic neurons (top) and anti-SMN (middle) 
to reveal the level and distribution of SMN protein. The lowest row 
shows an overlay of the ChAT (red) and SMN (green) signals. (a) Smn1 
+/−  carrier mouse injected with phosphate-buffered saline. (b) Smn1 
−/− disease mouse injected with PBS. (c1, c2) Smn1 −/− disease mice 
injected with scAAV9-4xsU7. Bar size = 50 µm.
a b c1 c2
ChAT
SMN
Overlay
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LED torch lamp. Usually, 5 µl of virus were injected at P0 (day of birth) and 
again at P1 through a glass capillary (microhematocrit tubes non heparin-
ized, ø ext. 1.45 mm, ø int. 0.95 mm, long 75.0 mm, Sovirel France, pulled 
in a micropipette puller model P97, Sutter Instrument S, Novato, CA) con-
nected via a tube to a 1 ml syringe that was used to control the liquid flow.
Monitoring of mouse development and performance. The overall condition 
and weight of the mice were initially recorded on a daily basis. As the mice 
reached a higher age, the intervals were increased to 2–3 days. The motil-
ity and strength were determined by the righting reflex (time to right from 
an inverted position). A second test consisted of measuring how long the 
mice could hold themselves with their hind legs grabbing the rim of a 50 ml 
Falcon tube, head downward, before falling into the tube that was padded 
with paper tissue to soften the fall. Additionally, a score from 0 to 4 was given 
depending on how far the hind legs were splayed, with 0 indicating that the 
legs touched each other and 4 representing the maximal possible distance.
RNA extraction and alternative splicing analysis of SMN2, Uspl1, and 
SMN2 exon 7 specific qPCR. Total RNA from transfected or virus-infected 
HeLa S2 cells was extracted with homemade Tri-Reagent as described.64 
Mouse tissues were homogenized in Tri-Reagent before extraction. 
Between 0.5–2 µg of RNA was reverse-transcribed with 20 pmoles of 
random hexamer or oligo d(T) with Affinity-Script Multi-Temp Reverse 
Transcriptase (Agilent Technologies, Basel, Switzerland) or with the 
PrimeScript RT Master Mix kit (Takara bIO eUROPE sas, Saint-Germain-
en-Laye, France) according to the manufacturers’ instructions. PCR for 
splicing analysis on agarose gels (SMN minigene and Uspl1) was per-
formed with the PCR FastStart 2× PCR Master Mix (Roche) and appro-
priate primers (see Supplementary Table S2). For the detection of exon 
7 containing SMN2 transcripts, the cDNA was analyzed by a SYBR-green 
based qPCR assay (mix as described for qPCR-based virus titration) using 
SMN-Ex7-Re(Fw) and SMN-Ex8-Re primers.
Quantitation of U7-ESE-B expression. To analyze U7-ESE-B expression, 
cDNA was synthesized in a coupled polyadenylation reverse transcrip-
tion reaction designed for short nonpolyadenylated RNAs.65 This cDNA 
was then used for a SYBR-green based qPCR analysis (mix as described 
for qPCR-based virus titration) with qPCR ESE Fw and universal reverse 
primers.65 As normalizer, U6 snRNA was analyzed with qPCR WT_U6 
Fw and the universal reverse primers. The primer sequences are listed in 
Supplementary Table S2.
Immunofluorescence analysis. Spinal cords were fixed in 4% paraformalde-
hyde (PFA) followed by incubation in 30% sucrose (w/v) overnight at 4°C 
each. The following day, the spinal cords were embedded in cryomolds using 
Tissue-Tek O.C.T. compound (Sakura Finetec, VWR International, Dietikon, 
Switzerland) and stored at −20°C. Sections of 50 µm thickness were cut with 
a microtome and transferred into 0.8% sodium azide in PBS. For all further 
treatments, the sections were incubated freely floating in wells of a 12-well 
plate, and transfers were done with a thin paint brush. First they were blocked 
in 3% bovine serum albumin (BSA) in PBS for 3 hours at RT followed by 
primary antibody incubation in 3% BSA and 0.3% TritonX-100 in PBS over-
night at 4°C on a rocker (for antibodies and dilutions see Supplementary 
Table S3). Following three wash steps in 0.1% TritonX-100 in PBS for 20 
minutes each, the sections were incubated with secondary antibody in 3% 
BSA and 0.3% TritonX-100 in PBS for 5 hours at RT or overnight at 4°C on 
a rocker in the dark. Subsequently, the sections were washed three times 20 
minutes in the dark with 0.1% TritonX-100 in PBS. Finally they were trans-
ferred onto glass slides, air-dried, mounted with homemade Moviol and 
stored at 4°C. The slides were analyzed with an Olympus Fluoview 1000-
BX61 microscope and Imaris 7.6 (Bitplane AG, Zürich, Switzerland) soft-
ware (Olympus Schweiz AG, Volketswil, Switzerland).
Diaphragms were dissected and stored at −20°C in RNAlater (Sigma-
Aldrich) for further analysis. During all staining steps, they were incubated 
freely floating in wells of a 24-well plate. After washing in PBS for 30 
minutes, NMJs were detected by incubation with α-Bungarotoxin in 3% 
BSA and 0.5% TritonX-100 in PBS at RT. Next, the samples were blocked 
for 3 hours at RT followed by primary antibody incubation in 3% BSA and 
0.5% TritonX-100 in PBS for 72 hours at 4°C on a rocker (for antibodies and 
dilutions see Supplementary Table S3). The incubation with secondary 
antibodies, all wash steps and the mounting were performed as described 
above for the spinal cord samples. The samples were analyzed with a Leica 
DMi8 microscope (Leica Microsystems, Heerbrugg, Switzerland) and Leica 
application suite X software and further evaluated with FiJi (Image J).
SUPPLEMENTARY MATERIAL
Figure S1. AAV vectors used in this work.
Figure S2. Muscle performance of SMA Δ7 mice injected with 
scAAV9 4xsU7 compared to uninjected or PBS-injected mice and wt 
or carrier littermates.
Figure S3. Photographs of SMNΔ7 Smn1−/− mice injected with 
scAAV9 4xsU7.
Figure S4. Conservation of active zones in diaphragm neuromuscu-
lar junctions (NMJs) of SMNΔ7 Smn1−/− mice injected with scAAV9 
4xsU7.
Figure S5. Scheme of AAV production and purification and EM pic-
tures of purified viruses.
Supplementary Methods (virus production) and Tables
Table S1. Amounts of cells/reagents used for virus production.
Table S2. Oligonucleotides used in this work.
Table S3. Antibodies and probes used in this work.
Description of supplementary videos
Supplementary File S2. Male SMA mouse D54-2-1, injected with 
2.73 × 1014 vg/kg scAAV9 4xsU7. Video taken on P78.
Supplementary File S3. Female SMA mouse D54-2–9, injected 
with 2.27 × 1014 vg/kg scAAV9 4xsU7, together with slightly larger 
female carrier littermate D54-2–3 and mother. Video taken on P78.
Supplementary File S4. Female SMA mouse D57-1-1, injected with 
6.25 × 1013 vg/kg scAAV9 4xsU7, together with adult female. Video 
taken on P49.
Supplementary References
ACKNOWLEDGMENTS
This work was supported by the Kanton Bern and the Swiss 
National Science Foundation through the grants 31003A_135644, 
31003A_153199, and through the NCCR RNA and Disease. We thank 
Pamela Y. Sandoval for cloning help, Mircea-Ioan Iacovache for EM 
analyses, David Stucki, and Romain Levayer for help with immunofluo-
rescence microscopy and Smita Saxena for critical comments on the 
manuscript. We also acknowledge AAV vectors and technical advice 
kindly offered by Bernard L. Schneider and Patrick Aebischer (EPFL 
Lausanne, Switzerland), Aurélie Goyenvalle and Luis Garcia (Université 
de Versailles, France) as well as Kathrin Meyer and Brian K. Kaspar 
(Nationwide Children’s Hospital, Columbus, OH, USA).
REFERENCES
 1. Crawford, TO and Pardo, CA (1996). The neurobiology of childhood spinal muscular 
atrophy. Neurobiol Dis 3: 97–110.
 2. Lefebvre, S, Bürglen, L, Reboullet, S, Clermont, O, Burlet, P, Viollet, L et al. (1995). 
Identification and characterization of a spinal muscular atrophy-determining gene.  
Cell 80: 155–165.
 3. Lunn, MR and Wang, CH (2008). Spinal muscular atrophy. Lancet 371: 2120–2133.
 4. Burnett, BG, Muñoz, E, Tandon, A, Kwon, DY, Sumner, CJ and Fischbeck, KH (2009). 
Regulation of SMN protein stability. Mol Cell Biol 29: 1107–1115.
 5. Cartegni, L and Krainer, AR (2002). Disruption of an SF2/ASF-dependent exonic 
splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. 
Nat Genet 30: 377–384.
 6. Kashima, T and Manley, JL (2003). A negative element in SMN2 exon 7 inhibits 
splicing in spinal muscular atrophy. Nat Genet 34: 460–463.
 7. Cartegni, L, Hastings, ML, Calarco, JA, de Stanchina, E and Krainer, AR (2006). 
Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and 
SMN2. Am J Hum Genet 78: 63–77.
 8. Kashima, T, Rao, N, David, CJ and Manley, JL (2007). hnRNP A1 functions with 
specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 16: 3149–3159.
 9. Marquis, J, Meyer, K, Angehrn, L, Kämpfer, SS, Rothen-Rutishauser, B and 
Schümperli, D (2007). Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected 
by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol Ther 15: 
1479–1486.
1804 www.moleculartherapy.org vol. 24 no. 10 oct. 2016
Official journal of the American Society of Gene & Cell Therapy
U7 RNA-mediated SMA Somatic Gene Therapy
 10. Monani, UR, Sendtner, M, Coovert, DD, Parsons, DW, Andreassi, C, Le, TT et al. 
(2000). The human centromeric survival motor neuron gene (SMN2) rescues 
embryonic lethality in SMN(−/−) mice and results in a mouse with spinal muscular 
atrophy. Hum Mol Genet 9: 333–339.
 11. Meyer, K, Marquis, J, Trüb, J, Nlend Nlend, R, Verp, S, Ruepp, MD et al. (2009). 
Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated 
splicing modulation. Hum Mol Genet 18: 546–555.
 12. Nlend Nlend, R, Meyer, K and Schümperli, D (2010). Repair of pre-mRNA splicing: 
prospects for a therapy for spinal muscular atrophy. RNA Biol 7: 430–440.
 13. Porensky, PN and Burghes, AH (2013). Antisense oligonucleotides for the treatment of 
spinal muscular atrophy. Hum Gene Ther 24: 489–498.
 14. Le, TT, Pham, LT, Butchbach, ME, Zhang, HL, Monani, UR, Coovert, DD et al. (2005). 
SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) 
gene, extends survival in mice with spinal muscular atrophy and associates with full-
length SMN. Hum Mol Genet 14: 845–857.
 15. Hua, Y, Vickers, TA, Okunola, HL, Bennett, CF and Krainer, AR (2008). Antisense 
masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in 
transgenic mice. Am J Hum Genet 82: 834–848.
 16. Hua, Y, Liu, YH, Sahashi, K, Rigo, F, Bennett, CF and Krainer, AR (2015). Motor neuron 
cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe 
transgenic mouse models. Genes Dev 29: 288–297.
 17. Passini, MA, Bu, J, Roskelley, EM, Richards, AM, Sardi, SP, O’Riordan, CR et al. (2010). 
CNS-targeted gene therapy improves survival and motor function in a mouse model 
of spinal muscular atrophy. J Clin Invest 120: 1253–1264.
 18. Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM et al. (2010). 
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal 
delivery of SMN. Nat Biotechnol 28: 271–274.
 19. Dominguez, E, Marais, T, Chatauret, N, Benkhelifa-Ziyyat, S, Duque, S, Ravassard, P 
et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence 
rescues SMA mice. Hum Mol Genet 20: 681–693.
 20. Valori, CF, Ning, K, Wyles, M, Mead, RJ, Grierson, AJ, Shaw, PJ et al. (2010). Systemic 
delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular 
atrophy. Sci Transl Med 2: 35ra42.
 21. Glascock, JJ, Shababi, M, Wetz, MJ, Krogman, MM and Lorson, CL (2012). Direct 
central nervous system delivery provides enhanced protection following vector 
mediated gene replacement in a severe model of spinal muscular atrophy. Biochem 
Biophys Res Commun 417: 376–381.
 22. Duque, S, Joussemet, B, Riviere, C, Marais, T, Dubreil, L, Douar, AM et al. (2009). 
Intravenous administration of self-complementary AAV9 enables transgene delivery to 
adult motor neurons. Mol Ther 17: 1187–1196.
 23. Wirth, B, Barkats, M, Martinat, C, Sendtner, M and Gillingwater, TH (2015). Moving 
towards treatments for spinal muscular atrophy: hopes and limits. Expert Opin Emerg 
Drugs 20: 353–356.
 24. Gruber, A, Soldati, D, Burri, M and Schümperli, D (1991). Isolation of an active gene 
and of two pseudogenes for mouse U7 small nuclear RNA. Biochim Biophys Acta 1088: 
151–154.
 25. Zhang, ML, Lorson, CL, Androphy, EJ and Zhou, J (2001). An in vivo reporter system 
for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of 
SMA. Gene Ther 8: 1532–1538.
 26. Wu, Z, Yang, H and Colosi, P (2010). Effect of genome size on AAV vector packaging. 
Mol Ther 18: 80–86.
 27. Meyer, K, Ferraiuolo, L, Schmelzer, L, Braun, L, McGovern, V, Likhite, S et al. (2015). 
Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a 
dose-response study in mice and nonhuman primates. Mol Ther 23: 477–487.
 28. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK 
(2009). Intravascular AAV9 preferentially targets neonatal neurons and adult 
astrocytes. Nat Biotechnol 27: 59–65.
 29. Butchbach, ME, Edwards, JD and Burghes, AH (2007). Abnormal motor phenotype in 
the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol Dis 27: 207–219.
 30. Huo, Q, Kayikci, M, Odermatt, P, Meyer, K, Michels, O, Saxena, S et al. (2014). 
Splicing changes in SMA mouse motoneurons and SMN-depleted neuroblastoma 
cells: evidence for involvement of splicing regulatory proteins. RNA Biol 11:  
1430–1446.
 31. Liu, H, Shafey, D, Moores, JN and Kothary, R (2010). Neurodevelopmental 
consequences of Smn depletion in a mouse model of spinal muscular atrophy. 
J Neurosci Res 88: 111–122.
 32. Bäumer, D, Lee, S, Nicholson, G, Davies, JL, Parkinson, NJ, Murray, LM et al. (2009). 
Alternative splicing events are a late feature of pathology in a mouse model of spinal 
muscular atrophy. PLoS Genet 5: e1000773.
 33. Zhang, Z, Lotti, F, Dittmar, K, Younis, I, Wan, L, Kasim, M et al. (2008). SMN 
deficiency causes tissue-specific perturbations in the repertoire of snRNAs and 
widespread defects in splicing. Cell 133: 585–600.
 34. Neve, A, Trüb, J, Saxena, S and Schümperli, D (2016). Central and peripheral defects 
in motor units of the diaphragm of spinal muscular atrophy mice. Mol Cell Neurosci 
70: 30–41.
 35. Bevan, AK, Duque, S, Foust, KD, Morales, PR, Braun, L, Schmelzer, L et al. (2011). 
Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral 
tissues for pediatric disorders. Mol Ther 19: 1971–1980.
 36. Duque, SI, Arnold, WD, Odermatt, P, Li, X, Porensky, PN, Schmelzer, L et al. (2015). 
A large animal model of spinal muscular atrophy and correction of phenotype. Ann 
Neurol 77: 399–414.
 37. McCarty, DM (2008). Self-complementary AAV vectors; advances and applications. 
Mol Ther 16: 1648–1656.
 38. Hua, Y, Sahashi, K, Rigo, F, Hung, G, Horev, G, Bennett, CF et al. (2011). Peripheral 
SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy 
mouse model. Nature 478: 123–126.
 39. McCarty, DM, Young, SM Jr and Samulski, RJ (2004). Integration of adeno-associated 
virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819–845.
 40. Nowrouzi, A, Penaud-Budloo, M, Kaeppel, C, Appelt, U, Le Guiner, C, Moullier, P et al. 
(2012). Integration frequency and intermolecular recombination of rAAV vectors in 
non-human primate skeletal muscle and liver. Mol Ther 20: 1177–1186.
 41. Kaeppel, C, Beattie, SG, Fronza, R, van Logtenstein, R, Salmon, F, Schmidt, S et al. 
(2013). A largely random AAV integration profile after LPLD gene therapy. Nat Med 
19: 889–891.
 42. Donsante, A, Miller, DG, Li, Y, Vogler, C, Brunt, EM, Russell, DW et al. (2007). AAV 
vector integration sites in mouse hepatocellular carcinoma. Science 317: 477.
 43. Bell, P, Wang, L, Lebherz, C, Flieder, DB, Bove, MS, Wu, D et al. (2005). No evidence 
for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 12: 299–306.
 44. Li, H, Malani, N, Hamilton, SR, Schlachterman, A, Bussadori, G, Edmonson, SE et al. 
(2011). Assessing the potential for AAV vector genotoxicity in a murine model. Blood 
117: 3311–3319.
 45. Gil-Farina, I, Fronza, R, Kaeppel, C, Lopez-Franco, E, Ferreira, V, D’Avola, D et al. 
(2016). Recombinant AAV Integration Is Not Associated With Hepatic Genotoxicity in 
Nonhuman Primates and Patients. Mol Ther 24: 1100–1105.
 46. Egloff, S, O’Reilly, D and Murphy, S (2008). Expression of human snRNA genes from 
beginning to end. Biochem Soc Trans 36(Pt 4): 590–594.
 47. Voigt, T, Meyer, K, Baum, O and Schümperli, D (2010). Ultrastructural changes in 
diaphragm neuromuscular junctions in a severe mouse model for Spinal Muscular 
Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. 
Neuromuscul Disord 20: 744–752.
 48. Voigt, T, Neve, A and Schümperli, D (2014). The craniosacral progression of muscle 
development influences the emergence of neuromuscular junction alterations in a 
severe murine model for spinal muscular atrophy. Neuropathol Appl Neurobiol 40: 
416–434.
 49. Benkhelifa-Ziyyat, S, Besse, A, Roda, M, Duque, S, Astord, S, Carcenac, R et al. (2013). 
Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal 
cord and decreases disease severity in SMA mice. Mol Ther 21: 282–290.
 50. Gavrilina, TO, McGovern, VL, Workman, E, Crawford, TO, Gogliotti, RG, DiDonato, CJ 
et al. (2008). Neuronal SMN expression corrects spinal muscular atrophy in severe 
SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum Mol 
Genet 17: 1063–1075.
 51. McGovern, VL, Iyer, CC, Arnold, WD, Gombash, SE, Zaworski, PG, Blatnik, AJ III et al. 
(2015). SMN expression is required in motor neurons to rescue electrophysiological 
deficits in the SMNΔ7 mouse model of SMA. Hum Mol Genet 24: 5524–5541.
 52. Haurigot, V, Marcó, S, Ribera, A, Garcia, M, Ruzo, A, Villacampa, P, et al. (2013). 
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene 
therapy. The Journal of Clinical Investigation 123: 3254–3271.
 53. Zincarelli, C, Soltys, S, Rengo, G and Rabinowitz, JE (2008). Analysis of AAV serotypes 
1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 
16: 1073–1080.
 54. Rudnik-Schöneborn, S, Heller, R, Berg, C, Betzler, C, Grimm, T, Eggermann, T et al. 
(2008). Congenital heart disease is a feature of severe infantile spinal muscular 
atrophy. J Med Genet 45: 635–638.
 55. Bevan, AK, Hutchinson, KR, Foust, KD, Braun, L, McGovern, VL, Schmelzer, L et al. 
(2010). Early heart failure in the SMNDelta7 model of spinal muscular atrophy and 
correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 19: 3895–3905.
 56. Heier, CR, Satta, R, Lutz, C and DiDonato, CJ (2010). Arrhythmia and cardiac defects 
are a feature of spinal muscular atrophy model mice. Hum Mol Genet 19: 3906–3918.
 57. Shababi, M, Habibi, J, Yang, HT, Vale, SM, Sewell, WA and Lorson, CL (2010). Cardiac 
defects contribute to the pathology of spinal muscular atrophy models. Hum Mol 
Genet 19: 4059–4071.
 58. Naryshkin, NA, Weetall, M, Dakka, A, Narasimhan, J, Zhao, X, Feng, Z, et al. (2014). 
SMN2 splicing modifiers improve motor function and longevity in mice with spinal 
muscular atrophy. Science 345: 688–693.
 59. Zhao, X, Feng, Z, Ling, KKY, Mollin, A, Sheedy, J, Yeh, S, et al. (2016). 
Pharmacokinetics, pharmacodynamics and efficacy of a small molecule SMN2 splicing 
modifier in mouse models of spinal muscular atrophy. Hum Mol Genet doi: 10.1093/
hmg/ddw062.
 60. Rogalska, ME, Tajnik, M, Licastro, D, Bussani, E, Camparini, L, Mattioli, C et al. (2016). 
Therapeutic activity of modified U1 core spliceosomal particles. Nat Commun 7: 
11168.
 61. Towne, C, Raoul, C, Schneider, BL and Aebischer, P (2008). Systemic AAV6 delivery 
mediating RNA interference against SOD1: neuromuscular transduction does not alter 
disease progression in fALS mice. Mol Ther 16: 1018–1025.
 62. Goyenvalle, A, Babbs, A, Wright, J, Wilkins, V, Powell, D, Garcia, L et al. (2012). Rescue 
of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-
mediated exon skipping. Hum Mol Genet 21: 2559–2571.
 63. Grimm, D, Kay, MA and Kleinschmidt, JA (2003). Helper virus-free, optically 
controllable, and two-plasmid-based production of adeno-associated virus vectors of 
serotypes 1 to 6. Mol Ther 7: 839–850.
 64. Marquis, J, Kämpfer, SS, Angehrn, L and Schümperli, D (2009). Doxycycline-
controlled splicing modulation by regulated antisense U7 snRNA expression cassettes. 
Gene Ther 16: 70–77.
 65. Raczynska, KD, Ruepp, MD, Brzek, A, Reber, S, Romeo, V, Rindlisbacher, B et al. 
(2015). FUS/TLS contributes to replication-dependent histone gene expression by 
interaction with U7 snRNPs and histone-specific transcription factors. Nucleic Acids Res 
43: 9711–9728.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-ShareAlike 4.0 
International License. The images or other third party 
material in this article are included in the article's Creative 
Commons license, unless indicated otherwise in the credit 
line; if the material is not included under the Creative 
Commons license, users will need to obtain permission from 
the license holder to reproduce the material. To view a copy 
of this license, visit http://creativecommons.org/licenses/by-
nc-sa/4.0/
© The Author(s) (2016)
Molecular Therapy vol. 24 no. 10 oct. 2016 1805
